The Last Full Measure
2020
Search results
Jul 10, 2023 · Veteran Oncology Researcher to Guide Investment in Breakthrough Cancer Treatments. LOS ANGELES – July 10, 2023 – Stand Up To Cancer® (SU2C) today announced that Julian Adams, Ph.D., a longtime oncology researcher and retired pharmaceutical industry chief executive, was named the organization’s first Chief Science Officer.
Dec 8, 2023 · LOS ANGELES – December 8, 2023 – Stand Up To Cancer® (SU2C) today announced the appointment of Julian Adams, Ph.D., as president and chief executive officer, which will be effective on January 1, 2024.
Julian Adams, PhD, is a scientist who is world-renowned for his extraordinary success in developing new molecules that impact human disease as well as for While director of medicinal chemistry at Boehringer Ingelheim, Dr. Adams developed the drug Viramune® (nevirapine) for HIV.
President and CEO, Stand Up To Cancer. Julian Adams, Ph.D., is president and chief executive officer of Stand Up To Cancer, and among the world’s foremost oncology researchers.
Jul 10, 2023 · LOS ANGELES, July 10, 2023 /PRNewswire/ -- Stand Up To Cancer ® (SU2C) today announced that Julian Adams, Ph.D., a longtime oncology researcher and retired pharmaceutical industry chief...
Dec 11, 2023 · Advertisement. Stand Up To Cancer (SU2C) announced December 8 the appointment of Julian Adams, PhD, as president and chief executive officer, which will be effective on January 1, 2024.
Julian Adams, PhD. Chairman. Dr. Julian Adams, has accumulated a wealth of experience with over 40 years in oncology research, development, and leadership. Prior to his retirement in October 2022, he served as Chief Executive Officer of Gamida Cell (NASDAQ:GMDA), a commercial-stage biopharmaceutical company working to develop cell therapies for ...
